Literature DB >> 14972326

Glycogenosis type II: identification and expression of three novel mutations in the acid alpha-glucosidase gene causing the infantile form of the disease.

Anna Lisa E Montalvo1, Roberta Cariati, Marta Deganuto, Veronica Guerci, Rodolfo Garcia, Giovanni Ciana, Bruno Bembi, Maria Gabriela Pittis.   

Abstract

Glycogenosis type II (GSDII) is an autosomal recessive disorder due to the deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). We identified three novel point mutations, C399A, T1064C, and C2104T, in three unrelated Italian patients with the infantile form of the disease. The C399A mutation was present in homozygosity in proband 1. The C >A transition introduces a premature stop signal in exon 2 resulting in no enzyme production that is correlated with the severe clinical phenotype in this patient. The other two nucleotide changes were missense mutations. The T1064C mutation, which changes Leu in position 355 into Pro, was carried in homozygosity by proband 2. The C2104T nucleotide change, which substitutes Arg 702 into Cys, was present in proband 3 in combination with a known severe mutation DeltaI17-18. The in vitro expression in COS-1 cells of T1064C and C2104T constructs demonstrated no enzymatic activity with respect to the negative control cells. Western blot analysis revealed that both T1064C and C2104T mutant proteins produced in COS-1 cells migrated in SDS-PAGE as the GAA inactive precursor of 110kDa. Immunofluorescence detection of mutant alpha-glucosidases showed enzyme localization primarily in the ER-Golgi compartment, suggesting that T1064C and C2104T mutations could affect the normal processing and stability of the enzyme. In vitro studies demonstrated that the same degree of deficiency in T1064C and C2104T mutations, which is in contrast with patient phenotype. A better correlation was observed with the in vivo studies since proband 2, with a less severe phenotype, presented with low residual enzyme activity while in proband 3, with a classic severe infantile onset GSDII, fibroblast enzyme activity was completely absent.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14972326     DOI: 10.1016/j.ymgme.2003.11.011

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  10 in total

1.  Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase.

Authors:  Samarjit Patnaik; Wei Zheng; Jae H Choi; Omid Motabar; Noel Southall; Wendy Westbroek; Wendy A Lea; Arash Velayati; Ehud Goldin; Ellen Sidransky; William Leister; Juan J Marugan
Journal:  J Med Chem       Date:  2012-06-08       Impact factor: 7.446

2.  Identification and Functional Characterization of GAA Mutations in Colombian Patients Affected by Pompe Disease.

Authors:  Mónica Yasmín Niño; Heidi Eliana Mateus; Dora Janeth Fonseca; Marian A Kroos; Sandra Yaneth Ospina; Juan Fernando Mejía; Jesús Alfredo Uribe; Arnold J J Reuser; Paul Laissue
Journal:  JIMD Rep       Date:  2012-04-19

3.  Evaluation of 2-thioxo-2,3,5,6,7,8-hexahydropyrimido[4,5-d]pyrimidin-4(1H)-one analogues as GAA activators.

Authors:  Juan J Marugan; Wei Zheng; Omid Motabar; Noel Southall; Ehud Goldin; Ellen Sidransky; Ronald A Aungst; Ke Liu; Subir Kumar Sadhukhan; Christopher P Austin
Journal:  Eur J Med Chem       Date:  2010-02-01       Impact factor: 6.514

4.  Molecular genetics of late onset glycogen storage disease II in Italy.

Authors:  M G Pittis; M Filocamo
Journal:  Acta Myol       Date:  2007-07

5.  A new resorufin-based alpha-glucosidase assay for high-throughput screening.

Authors:  Omid Motabar; Zhen-Dan Shi; Ehud Goldin; Ke Liu; Noel Southall; Ellen Sidransky; Christopher P Austin; Gary L Griffiths; Wei Zheng
Journal:  Anal Biochem       Date:  2009-04-14       Impact factor: 3.365

6.  Discovery of a novel noniminosugar acid α glucosidase chaperone series.

Authors:  Jingbo Xiao; Wendy Westbroek; Omid Motabar; Wendy A Lea; Xin Hu; Arash Velayati; Wei Zheng; Noel Southall; Ann Marie Gustafson; Ehud Goldin; Ellen Sidransky; Ke Liu; Anton Simeonov; Rafael J Tamargo; Antonia Ribes; Leslie Matalonga; Marc Ferrer; Juan J Marugan
Journal:  J Med Chem       Date:  2012-08-17       Impact factor: 7.446

7.  Variable clinical features and genotype-phenotype correlations in 18 patients with late-onset Pompe disease.

Authors:  Jousef Alandy-Dy; Marie Wencel; Kathy Hall; Julie Simon; Yanjun Chen; Erik Valenti; Jade Yang; Deeksha Bali; Anita Lakatos; Namita Goyal; Tahseen Mozaffar; Virginia Kimonis
Journal:  Ann Transl Med       Date:  2019-07

8.  Functional characterization of the common c.-32-13T>G mutation of GAA gene: identification of potential therapeutic agents.

Authors:  Andrea Dardis; Irene Zanin; Stefania Zampieri; Cristiana Stuani; Annalisa Pianta; Milena Romanello; Francisco E Baralle; Bruno Bembi; Emanuele Buratti
Journal:  Nucleic Acids Res       Date:  2013-10-22       Impact factor: 16.971

9.  Glycogen Reduction in Myotubes of Late-Onset Pompe Disease Patients Using Antisense Technology.

Authors:  Elisa Goina; Paolo Peruzzo; Bruno Bembi; Andrea Dardis; Emanuele Buratti
Journal:  Mol Ther       Date:  2017-06-16       Impact factor: 11.454

10.  The phenotype, genotype, and outcome of infantile-onset Pompe disease in 18 Saudi patients.

Authors:  Zuhair N Al-Hassnan; Ola A Khalifa; Dalal K Bubshait; Sahar Tulbah; Maarab Alkorashy; Hamad Alzaidan; Mohammed Alowain; Zuhair Rahbeeni; Moeen Al-Sayed
Journal:  Mol Genet Metab Rep       Date:  2018-02-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.